Ozempic’s Anger Twist Stuns Researchers

Shelves filled with various medication boxes and containers in a pharmacy

Popular weight-loss drugs like Ozempic and Wegovy now appear to do something nobody expected: they may weaken the leap from hot-headed impulse to violent action.

Story Snapshot

Rutgers researchers found the usual link between impulsivity and violence was about 62% weaker in current GLP‑1 users than former users ^[1].
The connection between alcohol use and violence was about 52% weaker, though that result was less consistent ^[1].
The study is observational and cross-sectional, so it cannot prove these drugs actually reduce violence ^[1].
The findings hint at brain effects on reward and impulse control that go far beyond shrinking waistlines ^[7].

What the Rutgers study really found about Ozempic, Wegovy, and violence

Rutgers researchers dug into survey data from adults who had used glucagon-like peptide 1 medications, the class that includes Ozempic and Wegovy, and asked two blunt questions: how impulsive are you, and how often do you engage in violent behavior ^[1]. Violent behavior here meant real-world aggressive acts, not just bad moods. Across the full sample, people who were more impulsive or drank more reported more violence, which matches decades of criminology and psychology work ^[1].

The twist came when the team split people into current users versus former users of these drugs. Among former users, impulsive people and heavier drinkers were far more likely to report violence, fitting the old pattern ^[1]. Among current users, that pattern was much weaker. The link between impulsivity and violence was about 62% weaker in current users, and the alcohol–violence link was about 52% weaker, although that second number bounced around more in sensitivity checks ^[1].

How could a diabetes drug possibly touch violent behavior?

Glucagon-like peptide 1 receptor agonists were built to help control blood sugar and lower appetite, but they also act in the brain. Review studies show these drugs can change reward processing, dampen cravings, and alter stress responses, including dopamine signaling tied to addiction and compulsive behavior ^[7]. The Rutgers authors leaned on that science to argue a simple idea: the drugs may not erase impulsive urges, but they might weaken how often those urges turn into punches, threats, or worse ^[1].

One coauthor compared the effect to what cognitive behavioral therapy tries to do: stretch the gap between a spike of anger and the moment someone acts on it ^[2]. If that picture holds, a person might still feel the urge to snap, still drink too much at times, but be less likely to cross the line into actual violence. This fits a personal-responsibility frame: the medication might give some people a little more internal brake power, but it does not replace moral choice or law enforcement.

Why this is not proof that Ozempic cuts crime

Headlines rushed to say these drugs “reduce violent behavior,” but the study’s own authors were far more careful. The research is observational and cross-sectional, which means they took a snapshot in time instead of tracking people before and after starting the drug ^[1]. That design can show association, not cause and effect. We do not know whether the drugs softened behavior, or calmer, more stable people were simply more likely to stay on them.

Wild!

GLP-1 drugs: Ozempic and Wegovy linked to drop in violent behavior, a Rutgers University study says https://t.co/m0Qc81JMnF

— K J Gillenwater (@kjgillenwater) June 18, 2026

The study also relied on self-report for both violence and medication status, which always raises questions about memory and honesty. The full models, control variables, and confidence intervals are not laid out in popular summaries, so readers cannot see how results shift under different assumptions ^[1].

Where the evidence could go next if we stay honest about limits

Even with those limits, the signal is intriguing enough to deserve real testing instead of hype. The clean way forward would be longitudinal studies that follow people before, during, and after starting these medications to see whether impulsivity, drinking, and violent acts actually drop over time ^[9]. Active-comparator studies could match new GLP‑1 users to similar people on other diabetes or weight-loss drugs to see if there is anything unique going on with this class.

Researchers also need to get beyond self-report. That means lab tasks that measure impulse control, brain imaging to see whether reward circuits change, and hard outcomes like arrests or hospital visits rather than only survey checkboxes ^[7]^[9]. Replication in other countries and different populations will matter too, so we can tell whether this is a universal brain effect or a quirk of one sample.